Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
kidney cancer
Biotech
Arcus drops promising data on HIF-2a candidate in kidney cancer
With new data on Arcus' HIF-2a inhibitor, one group of analysts figures the company could give Merck’s Welireg a run for its money in kidney cancer.
Fraiser Kansteiner
Oct 24, 2024 2:48pm
Allarity loses rights to Novartis cancer drug over payments
Feb 2, 2024 9:09am
Merck's HIF-2α med nabbed in Peloton buyout, keeps on delivering
Sep 18, 2020 3:00am
Dana-Farber researchers spot early kidney cancer with blood test
Jun 22, 2020 11:00am
Why 'hot' kidney tumors don't respond to PD-1 blockers
May 29, 2020 11:00am
Merck backs up Peloton buyout with promising kidney cancer data
May 13, 2020 5:00pm
